ES2118058T3 - Factor de crecimiento de las celulas t. - Google Patents

Factor de crecimiento de las celulas t.

Info

Publication number
ES2118058T3
ES2118058T3 ES89117317T ES89117317T ES2118058T3 ES 2118058 T3 ES2118058 T3 ES 2118058T3 ES 89117317 T ES89117317 T ES 89117317T ES 89117317 T ES89117317 T ES 89117317T ES 2118058 T3 ES2118058 T3 ES 2118058T3
Authority
ES
Spain
Prior art keywords
growth factor
cells
support
present
cell growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89117317T
Other languages
English (en)
Inventor
Snick Jacques Van
Catherine Uyttenhove
Richard J Simpson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Application granted granted Critical
Publication of ES2118058T3 publication Critical patent/ES2118058T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5425—IL-9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Abstract

LA PRESENTE INVENCION ES RELATIVA GENERALMENTE AL FACTOR DE CRECIMIENTO DE CELULAS T. MAS PARTICULARMENTE, LA PRESENTE INVENCION ES RELATIVA AL FACTOR DE CRECIMIENTO DE CELULAS T, LAS CUALES CONTIENEN UNA GLICOPROTEINA LA CUAL SOPORTA "INTERLEUQUIN2" E "INTERLEUQUIN-4" CON INDEPENCIA DEL DESARROLLO DE LA CELULA T DE SOPORTE, ESPECIALMENTE DE FUENTES HUMANAS Y DE RATONES Y ADEMAS LA CUAL ES CAPAZ DE AUMENTAR LA PROLIFERACION DE CELULAS QUE RESPONDEN A IL3- O IL4-. INCLUSO MAS PARTICULARMENTE, LA PRESENTE INVENCION ES RELATIVA AL FACTOR DE CRECIMIENTO DE LA CELULA DE SOPORTE P40, COMPOSICIONES FARMACEUTICAS DE EL, ANTICUERPOS PARA EL Y CLONES MODIFICADOS DE SU DNA. LA PRESENTE INVENCION TAMBIEN CONTEMPLA UN METODO PARA INDUCIR LA PROLIFERACION DE CELULAS DE APOYO T , ASI COMO CELULAS QUE RESPONDEN POR IL3- E IL4-. EL FACTOR DE CRECIMIENTO DE LAS CELULAS T DE APOYO AQUI CONTEMPLADO SE USA ENLA ESTIMULACION DE CELULAS ESPECIFICAS DEL SISTEMA INMUNOLOGICO, SOLO O EN COMBINACION CON IL3 O IL4.
ES89117317T 1988-09-19 1989-09-19 Factor de crecimiento de las celulas t. Expired - Lifetime ES2118058T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/246,482 US5208218A (en) 1988-09-19 1988-09-19 T cell growth factor glycoproteins

Publications (1)

Publication Number Publication Date
ES2118058T3 true ES2118058T3 (es) 1998-09-16

Family

ID=22930867

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89117317T Expired - Lifetime ES2118058T3 (es) 1988-09-19 1989-09-19 Factor de crecimiento de las celulas t.

Country Status (12)

Country Link
US (2) US5208218A (es)
EP (1) EP0361284B1 (es)
JP (1) JP3223260B2 (es)
AT (1) ATE167519T1 (es)
AU (1) AU621661B2 (es)
CA (1) CA1341461C (es)
DE (1) DE68928710T2 (es)
DK (1) DK175845B1 (es)
ES (1) ES2118058T3 (es)
IE (1) IE81152B1 (es)
IL (1) IL91691A (es)
PT (1) PT91750B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587302A (en) * 1988-09-19 1996-12-24 Ludwig Institute For Cancer Research T cell growth factor
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
US5414071A (en) * 1989-05-23 1995-05-09 Genetics Institute, Inc. Human cytokine IL-9
US5580753A (en) * 1989-05-23 1996-12-03 Ludwig Institute For Cancer Research DNA encoding the human cytokine, interleukin-9
WO1991007186A1 (en) * 1989-11-21 1991-05-30 The University Of Melbourne Anti-inflammatory compositions and methods
US5132109A (en) * 1990-10-05 1992-07-21 Ludwig Institute For Cancer Research Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
US5250295A (en) * 1991-11-04 1993-10-05 The Regents Of The Univ. Of California Natural killer cell enhancing factor
WO1994006906A1 (en) * 1992-09-18 1994-03-31 Merck & Co., Inc. DNA ENCODING MURINE PRECURSOR INTERLEUKIN 1β CONVERTING ENZYME
TW257792B (es) * 1992-10-01 1995-09-21 Lilly Co Eli
US5643881A (en) * 1994-08-04 1997-07-01 Tampa Bay Research Institute Protein having anti-HIV activity and method for obtaining it
US6037149A (en) * 1995-08-24 2000-03-14 Magainin Pharmaceuticals Inc. DNA encoding human asthma associated factor 1
AU2007202406B2 (en) * 1995-08-24 2010-08-12 Ligand Pharmaceuticals Inc. Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
ATE484294T1 (de) * 1995-08-24 2010-10-15 Genaera Corp Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
WO1998024904A2 (en) 1996-12-02 1998-06-11 Magainin Pharmaceuticals Inc. Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
EP1401497B1 (en) 2001-06-08 2012-01-11 Genaera Corporation Methods for the modulation of il-13
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
DE602004028007D1 (de) * 2003-05-14 2010-08-19 Bayer Pharmaceuticals Corp Interleukin-9 antagonist-muteine und ihre pharmakologischen anwendungsverfahren
WO2009086516A1 (en) * 2007-12-28 2009-07-09 Kalos Therapeutics, Inc. Anti-proliferative compounds and their use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636463A (en) * 1984-04-05 1987-01-13 Scripps Clinic And Research Foundation Antibodies to human interleukin-2 induced by synthetic polypeptides
US5006459A (en) * 1986-03-31 1991-04-09 T Cell Sciences, Inc. Therapeutic and diagnostic methods using soluble T cell surface molecules
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
US5208218A (en) * 1988-09-19 1993-05-04 Ludwig Institute For Cancer Research T cell growth factor glycoproteins
JPH04500363A (ja) * 1989-05-24 1992-01-23 アボツト・ラボラトリーズ 心房ペプチド誘導体

Also Published As

Publication number Publication date
IE892983L (en) 1990-03-19
US5157112A (en) 1992-10-20
EP0361284A3 (en) 1990-09-05
ATE167519T1 (de) 1998-07-15
IE81152B1 (en) 2000-05-03
JP3223260B2 (ja) 2001-10-29
DK458889D0 (da) 1989-09-18
PT91750B (pt) 1995-05-31
AU4156389A (en) 1990-03-22
IL91691A (en) 1997-07-13
AU621661B2 (en) 1992-03-19
US5208218A (en) 1993-05-04
DE68928710D1 (de) 1998-07-23
JPH034796A (ja) 1991-01-10
EP0361284A2 (en) 1990-04-04
DK458889A (da) 1990-03-20
IL91691A0 (en) 1990-06-10
CA1341461C (en) 2004-10-26
DK175845B1 (da) 2005-03-29
PT91750A (pt) 1990-03-30
DE68928710T2 (de) 1999-02-11
EP0361284B1 (en) 1998-06-17

Similar Documents

Publication Publication Date Title
ES2118058T3 (es) Factor de crecimiento de las celulas t.
BR9506741A (pt) Aplicação de anticorpos anti-tnf como medicamentos para o tratamento de doenças que apresentam elevados niveis de interleuquin-5 no soro
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
MX9306220A (es) Ptp 1d: una proteina tirosina fosfatasa novedosa.
NL300353I1 (nl) Geneesmiddelen met monoclonale antilichamen, die specifiek zijn voor de menselijk epidermale groeifactorreceptor
ES2058083T3 (es) Anticuerpos monoclonales contra el factor humano de la necrosis tumoral (tnf) y su empleo.
BR0314038A (pt) Anticorpo humano isolado, método de tratar uma doença mediada com il-1 em um paciente, composição farmacêutica, cadeias pesada e leve, e, método de mapeamento de epitopo de um antìgeno selecionado
ES2169023T3 (es) Nueva 1alfa-hidroxi vitaminada d4 y nuevos intermedios y analogos.
ES2070919T3 (es) Separacion cromatografica de las proteinas del plasma, principalmente del factor viii, del factor de willebrand de la fibronectina y del fibrinogeno.
FI891226A0 (fi) Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
ES2082850T3 (es) Inmunoglobulinas preparadas geneticamente.
ES2193245T3 (es) Reactivos estables para la preparacion de radiofarmacos.
ATE96679T1 (de) Makromolekulare platin-antitumorverbindungen.
PT93966A (pt) Novo sistema de libertacao de anticorpos para modificadores de resposta biologica
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
DK0412149T3 (da) Anvendelse af IL-7 til tilvejebringelse af lægemidler til stimulering af blodpladeproduktion
DE69032816T2 (de) Verwendung von oncostatin m zur suppression von mhc antigenen
ATE54826T1 (de) Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
ES2061823T3 (es) Nueva proteina h que es capaz de fijarse a igg, gen que codifica dicha proteina h, y un procedimiento para producir dicha proteina h.
ATE431746T1 (de) Verwendung cd28 spezifischer monoklonaler antikörper zur stimulation von blutzellen, welche kein cd28 tragen
MX9301675A (es) Composiciones que contienen peptidos para inducir tolerancia de las celulas t a un antigeno.
DE69841322D1 (de) Hepatitis c rezeptorprotein cd81
ATE67507T1 (de) Immunotoxine, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
AR004093A1 (es) El uso de una proteina derivada de una quimioquina de mamifero y un medicamento util para movilizar celulas tronco hematopoyeticas.
ES2220256T1 (es) Albumina humana terapeutica con baja actividad para la fijacion de aluminio.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 361284

Country of ref document: ES